MaxCyte Statistics

Total Valuation

MaxCyte has a market cap or net worth of GBP 254.47 million. The enterprise value is 145.48 million.

Market Cap	254.47M
Enterprise Value	145.48M

Important Dates

The last earnings date was Tuesday, March 11, 2025.

Earnings Date	Mar 11, 2025
Ex-Dividend Date	n/a

Share Statistics

MaxCyte has 106.03 million shares outstanding. The number of shares has increased by 1.53% in one year.

Current Share Class	n/a
Shares Outstanding	106.03M
Shares Change (YoY)	+1.53%
Shares Change (QoQ)	+0.42%
Owned by Insiders (%)	1.44%
Owned by Institutions (%)	64.84%
Float	95.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.16
PB Ratio	1.54
P/TBV Ratio	1.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.44
EV / Sales	4.71
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.22

Financial Position

The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.09.

Current Ratio	10.88
Quick Ratio	10.09
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.62
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -18.73% and return on invested capital (ROIC) is -13.47%.

Return on Equity (ROE)	-18.73%
Return on Assets (ROA)	-12.60%
Return on Invested Capital (ROIC)	-13.47%
Return on Capital Employed (ROCE)	-22.89%
Revenue Per Employee	270,650
Profits Per Employee	-287,662
Employee Count	114
Asset Turnover	0.15
Inventory Turnover	0.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.73% in the last 52 weeks. The beta is 1.20, so MaxCyte's price volatility has been higher than the market average.

Beta (5Y)	1.20
52-Week Price Change	-31.73%
50-Day Moving Average	316.42
200-Day Moving Average	315.11
Relative Strength Index (RSI)	33.05
Average Volume (20 Days)	34,553

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MaxCyte had revenue of GBP 30.85 million and -32.79 million in losses. Loss per share was -0.31.

Revenue	30.85M
Gross Profit	25.18M
Operating Income	-40.89M
Pretax Income	-32.79M
Net Income	-32.79M
EBITDA	-37.45M
EBIT	-40.89M
Loss Per Share	-0.31

Full Income Statement

Balance Sheet

The company has 123.40 million in cash and 14.41 million in debt, giving a net cash position of 108.99 million or 1.03 per share.

Cash & Cash Equivalents	123.40M
Total Debt	14.41M
Net Cash	108.99M
Net Cash Per Share	1.03
Equity (Book Value)	164.75M
Book Value Per Share	1.56
Working Capital	124.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -22.05 million and capital expenditures -1.32 million, giving a free cash flow of -23.37 million.

Operating Cash Flow	-22.05M
Capital Expenditures	-1.32M
Free Cash Flow	-23.37M
FCF Per Share	-0.22

Full Cash Flow Statement

Margins

Gross margin is 81.62%, with operating and profit margins of -132.54% and -106.29%.

Gross Margin	81.62%
Operating Margin	-132.54%
Pretax Margin	-106.29%
Profit Margin	-106.29%
EBITDA Margin	-121.37%
EBIT Margin	-132.54%
FCF Margin	n/a

Dividends & Yields

MaxCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.53%
Shareholder Yield	-1.53%
Earnings Yield	-12.89%
FCF Yield	-9.19%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

MaxCyte has an Altman Z-Score of 7.01.

Altman Z-Score	7.01
Piotroski F-Score	n/a